The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase ...

Related: Drug firm taps Genentech, Amgen execs as key leaders ... biotech execs snag bonuses Why UCSF Health's latest building is the 'future coming' Related: Why UCSF Health's latest building ...

building on a decade of robust safety and efficacy data for Ocrevus in multiple sclerosis,” said Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of Global Product Development.

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

Medical marketers are ready to move away from AI as a buzzword while sports marketing opportunities emerge at Digital Pharma ...

But biotechnology leader Genentech, in part through its Advancing ... Inclusive Research Site Alliance to nine sites total, building on our existing partnerships to include two new ophthalmology ...